고려대학교안산병원 또는 고대안산병원은 경기도 안산시 단원구에 위치한 상급종합병원이다.

During the past decade, Korea University Ansan Hospital conducted 107 clinical trials. In the 10-year time frame, 107 clinical trials started and 31 clinical trials were completed, i.e. on average, 29% percent of trials that started reached the finish line to date. In the past 5 years, 57 clinical trials started and 27 clinical trials were completed. i.e. 47.4% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Korea University Ansan Hospital" #1 sponsor was "Eli Lilly and Company" with 12 trials, followed by "Korea University" with 12 trials sponsored, "Janssen Research & Development, LLC" with 11 trials sponsored, "Hoffmann-La Roche" with 9 trials sponsored and "Pfizer" with 9 trials sponsored. Other sponsors include 83 different institutions and companies that sponsored additional 66 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Korea University Ansan Hospital" #1 collaborator was "Inje University" with 7 trials as a collaborator, "Korea University" with 7 trials as a collaborator, "Severance Hospital" with 6 trials as a collaborator, "Seoul National University Hospital" with 5 trials as a collaborator and "Asan Medical Center" with 4 trials as a collaborator. Other collaborators include 133 different institutions and companies that were collaborators in the rest 99 trials.

According to Clinical.Site data, the most researched conditions in "Korea University Ansan Hospital" are "Chronic Hepatitis B" (8 trials), "Atopic Dermatitis" (7 trials), "Crohn Disease" (7 trials), "Hepatocellular Carcinoma" (6 trials) and "Ulcerative Colitis" (6 trials). Many other conditions were trialed in "Korea University Ansan Hospital" in a lesser frequency.

Most popular intervention types in "Korea University Ansan Hospital" are "Drug" (94 trials), "Biological" (23 trials), "Other" (21 trials), "Device" (7 trials) and "Procedure" (4 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (36 trials), "Etrolizumab" (4 trials), "Baricitinib" (3 trials), "Mirikizumab" (3 trials) and "Ozanimod" (3 trials). Other intervention names were less common.

The vast majority of trials in "Korea University Ansan Hospital" are 137 trials for "All" genders, 2 trials for "Female" genders and 1 trials for "Male" genders.

Currently, there are NaN active trials in "Korea University Ansan Hospital". 1 are not yet recruiting, 26 are recruiting, 18 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 67 completed trials in Korea University Ansan Hospital, undefined suspended trials, and 7 terminated clinical trials to date.

Out of the total trials that were conducted in Korea University Ansan Hospital, 6 "Phase 1" clinical trials were conducted, 24 "Phase 2" clinical trials and 59 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 24 trials, and there were also 8 trials that are defined as “Not Applicable".